18F-Fluorocholine PET/CT for the Staging and Follow-up of a Patient Suffering From Metastatic Parathyroid Carcinoma
- PMID: 40902141
- DOI: 10.1097/RLU.0000000000005825
18F-Fluorocholine PET/CT for the Staging and Follow-up of a Patient Suffering From Metastatic Parathyroid Carcinoma
Abstract
Parathyroid carcinoma (PC) is a rare disease, with a frequency of 0.005% of all malignancies. Approximately 30% of patients will develop metastases at some point in the disease. Nonsecreting PC represents <10% of all PC and is harder to diagnose. Here, we report the case of a patient suffering from metastatic nonsecreting PC who has been (and still is) monitored for 4.5 years with 18F-fluorocholine PET/CT.
Keywords: PET/CT; follow-up; parathyroid carcinoma; staging.
Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Conflicts of interest and sources of funding: none declared.
References
-
- Fingeret AL. Contemporary evaluation and management of parathyroid carcinoma. JCO Oncol Pract. 2021;17:17–21.
-
- Alberti A, Smussi D, Zamparini M, et al. Treatment and outcome of metastatic parathyroid carcinoma: a systematic review and pooled analysis of published cases. Front Oncol. 2022;12:997009.
-
- Morand GB, Helmchen BM, Steinert HC, et al. 18F-Choline-PET in parathyroid carcinoma. Oral Oncol. 2018;86:314–315.
-
- Deandreis D, Terroir M, Al Ghuzlan A, et al. 18Fluorocholine PET/CT in parathyroid carcinoma: a new tool for disease staging? Eur J Nucl Med Mol Imaging. 2015;42:1941–1942.
-
- Hatzl M, Röper-Kelmayr JC, Fellner FA, et al. 18F-Fluorocholine, 18F-FDG, and 18F-Fluoroethyl Tyrosine PET/CT in parathyroid cancer. Clin Nucl Med. 2017;42:448–450.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
